Scalper1 News
Small biotech Orexigen Therapeutics (OREX) surged 48.5% to a four-year high in enormous volume Tuesday on news that its obesity drug might not only make people look better but also help them live longer. Late Monday, Orexigen disclosed that an interim analysis of an ongoing trial looking at cardiovascular events such as heart attacks and strokes in patients on its drug Contrave found a 41% reduction in events for patients on the drug vs. those on Scalper1 News
Scalper1 News